博瑞医药：第三季度营收为3.37亿元

Core Insights - The core viewpoint of the article highlights the financial performance of Borui Pharmaceutical (688166.SH) for Q3 2025, indicating a decline in net profit despite a slight increase in revenue [1] Financial Performance - Q3 revenue reached 337 million yuan, representing a year-on-year increase of 5.54% [1] - Q3 net profit was 33.15 million yuan, showing a year-on-year decrease of 53.34% [1] - Revenue for the first three quarters totaled 874 million yuan, reflecting a year-on-year decline of 10.50% [1] - Net profit for the first three quarters was 50.32 million yuan, down 71.64% year-on-year [1] Factors Affecting Performance - The decline in performance is primarily attributed to changes in flu trends and intensified market competition, leading to decreased demand and prices for oseltamivir raw materials and formulations [1] - Revenue and gross profit from antiviral products significantly decreased [1] - Sales of high-margin antifungal products declined due to fluctuations in customer demand, further impacting profit performance [1]